China's H1N1 Flu Vaccine Said To Pass Phase I Trials
This article was originally published in PharmAsia News
The Health Ministry in China declared its version of an H1N1 flu vaccine has passed Phase I trials showing it to be safe and efficacious. The vaccine already is being prepared for Phase II trials after the initial round turned up no severe adverse reactions among more than 13,000 volunteers. Health Minister Chen Zhu held a news conference to announce the results and received his second injection of the vaccine. (Click here for more
You may also be interested in...
In final rule describing the types of evidence the agency will consider in determining the ‘intended use’ of a product, FDA rejects industry requests to exclude ‘circumstances surrounding distribution’ and product design or composition.
User fees for FY 2021 were set to increase nearly 11%, but could have gone even higher; a new notice will be issued but timing is unclear.
As Exo awaits FDA clearance for its handheld ultrasound device, it will use the new funding for planned commercialization. Exo has raised more than $320m to date.